Meta-Analysis Plan for MID207941: A Study to Evaluate Risk Factors for Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in a COPD Population of Patients Treated with GW685698 + GW642444 (Fluticasone Furoate + Vilanterol); GW642444 (Vilanterol); CCI18781 (Fluticasone Propionate); GR33343 (Salmeterol); CCI18781+ GR33343 (Fluticasone Propionate + Salmeterol) and Placebo

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  Data from GSK Sponsored Completed Clinical Trials: HZC102870, HZC102970, SCO100250, SCO40043, SCO30003

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No